^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MUC16 elevation

    i
    Other names: MUC16, Mucin 16, Cell Surface Associated, Ovarian Cancer-Related Tumor Marker CA125, Ovarian Carcinoma Antigen CA125, Mucin-16, CA125, CA125 Ovarian Cancer Antigen, Mucin-16 Short Isoform, Mucin-16 Long Isoform, CA-125, MUC-16
    Entrez ID:
    94025
    Related biomarkers:
    Expression
    Mutation
    Others
    Apply
    Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) (NCT05445778)
    Phase 3
    ImmunoGen, Inc.
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    12/27/2022
    Primary completion :
    03/01/2027
    Completion :
    04/01/2029
    FOLR1 • BRCA • MUC16
    |
    FOLR1 expression • MUC16 elevation
    |
    Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
    Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy (NCT06083844)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    12/12/2023
    Primary completion :
    09/30/2025
    Completion :
    09/30/2027
    BRCA1 • BRCA2 • MUC16
    |
    MUC16 elevation
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • cyclophosphamide
    Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection (NCT05334069)
    Phase N/A
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    08/01/2022
    Primary completion :
    01/31/2025
    Completion :
    02/01/2025
    MUC16
    |
    MUC16 elevation
    Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer (NCT05051722)
    Phase N/A
    Mayo Clinic
    Recruiting
    Last update posted :
    05/16/2024
    Initiation :
    08/03/2021
    Primary completion :
    06/30/2025
    Completion :
    12/30/2025
    MUC16
    |
    MUC16 elevation
    Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (FRAGILE) (NCT02828618)
    Phase N/A
    AGO Study Group
    Active, not recruiting
    Last update posted :
    05/09/2024
    Initiation :
    07/01/2016
    Primary completion :
    12/01/2024
    Completion :
    02/01/2025
    MUC16
    |
    MUC16 elevation
    Combination Therapy for Recurrent Ovarian Cancer (NCT05610735)
    Phase 1/2
    Sham Sunder Kakar
    Recruiting
    Last update posted :
    04/24/2024
    Initiation :
    05/01/2024
    Primary completion :
    11/01/2026
    Completion :
    11/01/2027
    MUC16
    |
    MUC16 elevation
    |
    pegylated liposomal doxorubicin
    Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (NCT01116648)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    04/08/2024
    Initiation :
    04/14/2010
    Primary completion :
    10/31/2018
    Completion :
    02/13/2025
    BRCA • MUC16
    |
    BRCA mutation • MUC16 elevation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer (NCT00408590)
    Phase 1
    Mayo Clinic
    Completed
    Last update posted :
    01/15/2024
    Initiation :
    04/19/2004
    Primary completion :
    08/01/2012
    Completion :
    11/07/2017
    MUC16 • CD4
    |
    MUC16 elevation
    Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers (NCT00803569)
    Phase 1
    Ludwig Institute for Cancer Research
    Completed
    Last update posted :
    10/04/2023
    Initiation :
    11/14/2008
    Primary completion :
    01/24/2011
    Completion :
    01/24/2011
    MUC16 • CTAG1B • CTAG2
    |
    MUC16 elevation
    |
    Leukine (sargramostim)
    Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (NCT02020707)
    Phase 1
    Mayo Clinic
    Active, not recruiting
    Last update posted :
    10/02/2023
    Initiation :
    02/24/2014
    Primary completion :
    06/30/2024
    Completion :
    06/30/2025
    MUC16
    |
    MUC16 elevation
    |
    Avastin (bevacizumab) • cisplatin • albumin-bound paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02122185)
    Phase 2
    University of Chicago
    Suspended
    Last update posted :
    08/28/2023
    Initiation :
    02/25/2015
    Primary completion :
    02/25/2025
    Completion :
    02/25/2025
    CEACAM5 • MUC16
    |
    MUC16 elevation
    |
    metformin
    IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (NCT06014528)
    Phase 2
    InxMed (Shanghai) Co., Ltd.
    Recruiting
    Last update posted :
    08/28/2023
    Initiation :
    09/06/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    MUC16
    |
    MUC16 elevation
    |
    pegylated liposomal doxorubicin • ifebemtinib (IN10018)
    MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) (NCT04111978)
    Phase 3
    Swiss GO Trial Group
    Recruiting
    Last update posted :
    06/27/2023
    Initiation :
    11/05/2020
    Primary completion :
    10/01/2025
    Completion :
    10/01/2030
    ER • MUC16
    |
    MUC16 elevation
    |
    letrozole
    Phase I Study of MOv18 IgE (CRUKD14/001) (NCT02546921)
    Phase 1
    Cancer Research UK
    Completed
    Last update posted :
    06/05/2023
    Initiation :
    02/16/2016
    Primary completion :
    06/22/2021
    Completion :
    07/30/2021
    MUC16
    |
    MUC16 elevation
    |
    MOv18 IgE
    GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (NCT02759588)
    Phase 1b
    Genelux Corporation
    Completed
    Last update posted :
    01/05/2023
    Initiation :
    05/01/2016
    Primary completion :
    12/31/2021
    Completion :
    12/31/2022
    MUC16
    |
    MUC16 elevation
    |
    Avastin (bevacizumab) • olvimulogene nanivacirepvec (GL-ONC1)
    Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients (ICON9) (NCT03278717)
    Phase 3
    University College, London
    Recruiting
    Last update posted :
    09/27/2022
    Initiation :
    06/15/2018
    Primary completion :
    12/01/2023
    Completion :
    12/01/2023
    BRCA • MUC16
    |
    BRCA mutation • MUC16 elevation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer (NCT03056833)
    Phase 1
    Ronald Buckanovich
    Completed
    Last update posted :
    09/07/2022
    Initiation :
    06/10/2017
    Primary completion :
    06/01/2020
    Completion :
    08/01/2022
    MUC16
    |
    MUC16 elevation
    |
    carboplatin • paclitaxel • Kisqali (ribociclib)
    Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer (NCT03794778)
    Phase 4
    Women's Hospital School Of Medicine Zhejiang Un...
    Active, not recruiting
    Last update posted :
    07/18/2022
    Initiation :
    03/19/2019
    Primary completion :
    03/31/2024
    Completion :
    03/31/2024
    MUC16
    |
    MUC16 elevation
    |
    carboplatin • paclitaxel • pegylated liposomal doxorubicin • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal
    Exploring the Potential of Novel Biomarkers Based on Plasma microRNAs for a Better Management of Pelvic Gynecologic Tumors (GYNO-MIR) (NCT03776630)
    Phase N/A
    Assistance Publique - Hôpitaux de Paris
    Active, not recruiting
    Last update posted :
    06/30/2022
    Initiation :
    05/23/2019
    Primary completion :
    05/01/2023
    Completion :
    05/01/2027
    MUC16 • MIR200B
    |
    MUC16 elevation
    Safety Study of X-82 in Patients With Advanced Solid Tumors (NCT01296581)
    Phase 1
    Tyrogenex
    Completed
    Last update posted :
    02/28/2022
    Initiation :
    02/01/2011
    Primary completion :
    01/01/2014
    Completion :
    01/01/2017
    MUC16
    |
    MUC16 elevation
    |
    Fumena (vorolanib)
    DDP ip Combined With AG in PDAC With Peritoneal Metastasis (NCT05222204)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    02/03/2022
    Initiation :
    07/02/2021
    Primary completion :
    07/02/2023
    Completion :
    07/02/2023
    MUC16
    |
    MUC16 elevation
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel
    Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer (NCT04518501)
    Phase 1/2
    Xing Xie
    Recruiting
    Last update posted :
    01/25/2022
    Initiation :
    07/01/2020
    Primary completion :
    01/01/2024
    Completion :
    01/01/2025
    BRCA1 • BRCA2 • MUC16
    |
    BRCA2 mutation • BRCA1 mutation • MUC16 elevation
    |
    Lynparza (olaparib) • AiRuiYi (fluzoparib) • arsenic trioxide
    Impact of Systematic Imaging for Follow up of Patients With Ovarian, Fallopian Tube or Primary Peritoneum Cancer (QUALOV) (NCT04826029)
    Phase N/A
    Assistance Publique - Hôpitaux de Paris
    Withdrawn
    Last update posted :
    12/10/2021
    Initiation :
    06/22/2021
    Primary completion :
    06/22/2021
    Completion :
    06/22/2021
    BRCA • MUC16
    |
    MUC16 elevation
    Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer (NCT04217798)
    Phase 2
    Peking Union Medical College Hospital
    Recruiting
    Last update posted :
    09/01/2021
    Initiation :
    05/21/2020
    Primary completion :
    03/01/2022
    Completion :
    06/01/2022
    MUC16
    |
    MUC16 elevation
    |
    Zejula (niraparib) • etoposide oral
    Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer (OVACURE) (NCT04072263)
    Phase 1/2
    Leiden University Medical Center
    Recruiting
    Last update posted :
    04/01/2021
    Initiation :
    08/01/2018
    Primary completion :
    08/01/2021
    Completion :
    12/01/2021
    MUC16
    |
    MUC16 elevation
    |
    carboplatin • paclitaxel
    Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00866697)
    Phase 3
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    02/16/2021
    Initiation :
    05/26/2009
    Primary completion :
    07/08/2012
    Completion :
    08/24/2017
    MUC16
    |
    MUC16 elevation
    |
    pazopanib
    Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer (AVANIRA3) (NCT04556071)
    Phase 2
    Xiaoxiang Chen
    Recruiting
    Last update posted :
    11/10/2020
    Initiation :
    11/06/2020
    Primary completion :
    03/01/2022
    Completion :
    10/01/2022
    HRD • MUC16
    |
    HRD • MUC16 elevation
    |
    Avastin (bevacizumab) • Zejula (niraparib)
    Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT02283658)
    Phase 2
    Mayo Clinic
    Completed
    Last update posted :
    10/23/2020
    Initiation :
    11/14/2014
    Primary completion :
    06/15/2016
    Completion :
    06/21/2018
    ER • MUC16
    |
    ER positive • MUC16 elevation
    |
    everolimus • letrozole
    A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) (NCT00889382)
    Phase 1/2
    Astellas Pharma Inc
    Completed
    Last update posted :
    11/19/2019
    Initiation :
    08/05/2009
    Primary completion :
    08/01/2014
    Completion :
    08/25/2014
    MUC16
    |
    MUC16 elevation
    |
    paclitaxel • linsitinib (ASP7487)
    Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT01747798)
    Phase 1
    Mayo Clinic
    Completed
    Last update posted :
    08/02/2019
    Initiation :
    11/02/2012
    Primary completion :
    01/10/2014
    Completion :
    04/06/2015
    MUC16
    |
    MUC16 elevation
    Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin (NCT00993616)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    07/23/2019
    Initiation :
    12/01/2009
    Primary completion :
    07/01/2012
    Completion :
    07/29/2012
    MUC16
    |
    MUC16 elevation
    |
    cisplatin • carboplatin • Beleodaq (belinostat)
    Quality of Life Associated With a Low-Risk Screening Program for Ovarian Cancer (NCT00511641)
    Phase N/A
    M.D. Anderson Cancer Center
    Unknown status
    Last update posted :
    06/24/2019
    Initiation :
    02/12/2002
    Primary completion :
    02/01/2020
    Completion :
    02/01/2021
    MUC16
    |
    MUC16 elevation
    EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT01489371)
    Phase 1
    Gynecologic Oncology Group
    Completed
    Last update posted :
    03/12/2019
    Initiation :
    07/09/2012
    Primary completion :
    12/30/2014
    Completion :
    01/27/2018
    MUC16
    |
    MUC16 elevation
    |
    cisplatin • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal
    Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer (NCT00278343)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    08/29/2018
    Initiation :
    04/01/2006
    Primary completion :
    06/01/2010
    Completion :
    01/15/2018
    MUC16
    |
    MUC16 elevation
    |
    Recentin (cediranib)
    Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab (NCT01223235)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    06/12/2018
    Initiation :
    10/01/2010
    Primary completion :
    09/01/2017
    Completion :
    09/01/2017
    ALK • MUC16
    |
    MUC16 elevation
    |
    Avastin (bevacizumab) • polyvalent vaccine-KLH conjugate